top of page

Our Process

Impact Opportunity


 KeraX  innovations hold the potential to prevent tens of thousands of avoidable blindness cases annually, restore quality of life and productivity to working-age individuals disproportionately affected, and reduce healthcare system burden by offering alternatives to costly and limited corneal transplants. 


We Discover, Develop, and Deploy these innovations, while measuring impact in relief of human suffering (Disability-Adjusted Life Years DALYs  averted), cost-effectiveness (<$100 per DALY averted), and lives touched.  

 

3DProcessMARGIN.png


Discover – Find and Validate 

  • Evaluate clinical and societal impact (customer), technical feasibility (product), and commercial potential (business). 

  • Key hypotheses are validated through stakeholder interviews, proof-of-concept development, and an initial business model.  

  • Early risk assessment is conducted, including IP, regulatory, and reimbursement considerations. 

Develop – Build and Pre-Clinical 

  • A functional prototype is developed and the business model refined. IP protection is initiated (e.g., provisional filing), and the go-to-market strategy is defined. 

  • A minimum viable product (MVP) is built and pre-clinical testing conducted. The IP strategy is expanded, potential licensees or partners identified, and the technology transfer and commercialization pathway established. A founder may be onboarded in case of a spinout. 

Deploy – Compliance and Launch 

  • Clinical trials are completed and regulatory milestones achieved. The product undergoes a soft launch with early market traction. 

  • Operational capabilities are established, commercial or strategic partnerships formed, and the product launched in key markets, supported by access to capital for scaling. 

 

bottom of page